



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Yingze Ye,
✉ yeyingze@whu.edu.cn
Xiaoxing Xiong,
✉ xiaoxingxiong@whu.edu.cn

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to Cancer Genetics and Oncogenomics, a section of the journal Frontiers in Genetics

RECEIVED 06 December 2022
ACCEPTED 08 December 2022
PUBLISHED 16 January 2023

CITATION

Hu X, Zhu H, Feng S, Wang C, Ye Y and Xiong X (2023), Corrigendum: Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma. *Front. Genet.* 13:1117731. doi: 10.3389/fgene.2022.1117731

COPYRIGHT

© 2023 Hu, Zhu, Feng, Wang, Ye and Xiong. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

Xinyao Hu^{1†}, Hua Zhu^{2,3†}, Shi Feng³, Chaoqun Wang³, Yingze Ye^{3*} and Xiaoxing Xiong^{1,2,3*}

¹Cancer Center, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, China, ²Department of Neurosurgery, The Affiliated Huzhou Hospital, Zhejiang University School of Medicine (Huzhou Central Hospital), Huzhou, China, ³Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China

KEYWORDS

TMCO3, ICB, diagnostics, immune infiltrates, LIHC

A Corrigendum on Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

by Hu X, Zhu H, Feng S, Wang C, Ye Y and Xiong X (2022). *Front. Genet.* 13:1006357. doi: 10.3389/fgene.2022.1006357

In the published article, there was an error regarding the **Affiliation** for “Xiaoxing Xiong^{2,3}.” As well as having affiliations 2,3, he should also have “1 Cancer Center, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, China.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.